acute myocardial infarction

Rivaroxaban reduces in-stent thrombosis in patients with acute coronary syndromes

Original title:&nbsp;Reduction of Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Rivaroxaban in ATLAS-ACS 2 TIMI 51.&nbsp;Reference:&nbsp;C. Michael Gibson et al. J Am Coll Cardiol 2013;62:286&ndash;90. There are few contemporary studies that investigated oral anticoagulation utility in patients with acute coronary syndromes and coronary angioplasty. Rivaroxaban is an oral anticoagulant that directly and<a href="https://solaci.org/en/2013/08/23/rivaroxaban-reduces-in-stent-thrombosis-in-patients-with-acute-coronary-syndromes/" title="Read more" >...</a>

Monoclonal antibodies to decrease peri-procedural myocardial damage

Original title:&nbsp;Effects of the P-Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention for Non&ndash;ST-Segment Elevation Myocardial Infarction Results of the SELECT-ACS Trial.&nbsp;Reference:&nbsp;Jean-Claude Tardif et al. J Am Coll Cardiol 2013;61:2048&ndash;55. The pathophysiology of myocardial injury after angioplasty is multifactorial but it is clear that inflammation and platelet activation play a major role. P-selectin<a href="https://solaci.org/en/2013/07/03/monoclonal-antibodies-to-decrease-peri-procedural-myocardial-damage/" title="Read more" >...</a>

High doses of Rosuvastatin in acute coronary syndromes

Original title:&nbsp;Rosuvastatin calcium in acute coronary sydromes&nbsp;Reference:&nbsp;Aggarwal, R. et al, Expert Opinion on Pharmacotherapy , Volume 14, Number 9, June 2013 , pp. 1215-1227(13). Lowering cholesterol of low density lipoproteins (LDL-C) by reducing inhibitors of 3-hydroxy-3-metilgutaril coenzyme A (HMGCoA) statins has proven advantageous for the survival of patients with acute coronary syndrome (ACS). These patients<a href="https://solaci.org/en/2013/06/19/high-doses-of-rosuvastatin-in-acute-coronary-syndromes/" title="Read more" >...</a>

Coronary angioplasty reduces the risk of spontaneous myocardial infarction in chronic stable patients.

Original title:&nbsp;Percutaneous Coronary Intervention Versus Optimal Medical Therapy for Prevention of Spontaneous Myocardial Infarction in Subjects With Stable Ischemic Heart Disease.&nbsp;Reference:&nbsp;Sripal Bangalore et al. Circulation. 2013;127:769-781 In the context of coronary angioplasty complications may arise, such as a periprocedural infarction. However, this event does not have the same clinical consequences compared to a spontaneous infarction.&nbsp;<a href="https://solaci.org/en/2013/02/26/coronary-angioplasty-reduces-the-risk-of-spontaneous-myocardial-infarction-in-chronic-stable-patients/" title="Read more" >...</a>

Periprocedural Infarction vs. Spontaneous Infarction: Prognostic Significance 

Original title:&nbsp;Comparison of the Prognosis of Spontaneous and Percutaneous Coronary Intervention&ndash;Related Myocardial Infarction.&nbsp;Reference:&nbsp;Sergio Leonardi, MD et al. Journal of the American College of Cardiology Vol. 60, No. 22, 2012 Clinical significance of myocardial infarction (MI) associated to coronary angioplasty is a controversial issue worldwide. Most of research on coronary disease includes it as a primary<a href="https://solaci.org/en/2012/12/03/periprocedural-infarction-vs-spontaneous-infarction-prognostic-significance/" title="Read more" >...</a>

Is a counter-pulsation balloon useful in myocardial infarction?

Original title:&nbsp;Intraaortic Balloon Support for Myocardial Infarction with Cardiogenic Shock (for the IABP-Shock II Trial Investigator)&nbsp;Reference:&nbsp;Holger T, et al. NEJM 367;14:1287 &nbsp; The rate of mortality in cardiogenic shock secondary to acute myocardial infarction (AMI) is high even in patients receiving early revascularization. The use of an intra-aortic balloon counter-pulsation pump (IABP) according to the<a href="https://solaci.org/en/2012/11/22/is-a-counter-pulsation-balloon-useful-in-myocardial-infarction/" title="Read more" >...</a>

To discontinue clopidogrel after a year of infarction can be risky

Reference: Charlot et al. European Heart Journal 2012 (in press). International guideline recommendations approve giving dual antiplatelet therapy for a period of not less than 12 months after acute myocardial infarction. However, the benefit is unknown if the therapy is extended beyond 12 months. Perhaps its extension could be particularly useful in patients receiving pharmacological<a href="https://solaci.org/en/2012/10/01/to-discontinue-clopidogrel-after-a-year-of-infarction-can-be-risky/" title="Read more" >...</a>

Hyperglycemia on admission, an excess risk for infarction

Reference: Planer et al. International Journal of Cardiology 2012 (in press) Prognosis of patients enrolled in acute myocardial infarction with ST segment elevation (STEMI) has improved markedly, particularly as a result of reperfusion therapy. Despite these improvements, patients with diabetes mellitus (DM) are a high risk group in the short and long term compared with<a href="https://solaci.org/en/2012/09/01/hyperglycemia-on-admission-an-excess-risk-for-infarction/" title="Read more" >...</a>

IAM y múltiples vasos, ¿podemos realizar un solo procedimiento?

Initial Complete Revascularization vs. Staged Revascularization in Patients with STEMI and Multivessel Disease

In patients with ST-segment elevation acute myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (primary PCI), multivessel disease is observed in up to 40% of cases. The optimal timing for revascularizing non-culprit lesions in these patients without cardiogenic shock remains a controversial issue. European guidelines recommend completing revascularization during the initial procedure or within 45&nbsp;days<a href="https://solaci.org/en/2024/07/17/initial-complete-revascularization-vs-staged-revascularization-in-patients-with-stemi-and-multivessel-disease/" title="Read more" >...</a>

Cilostazol en pacientes diabéticos con revascularización periférica endovascular: Un paso más allá de la mejoría sintomática

Glycemic Control and Coronary Stent Failure

Diabetic patients have twice as high a risk of developing coronary artery disease (CAD). Additionally, CAD increases mortality risk. Patients with a history of percutaneous coronary intervention (PCI) tend to need repeat revascularization, even with second generation stents. To date, there are few studies assessing the role of glycemic control in stent failure, stent thrombosis,<a href="https://solaci.org/en/2024/06/13/glycemic-control-and-coronary-stent-failure/" title="Read more" >...</a>

Top